Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Completed · Phase 2

Conditions studied: Stasis Dermatitis

In brief

This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment 2% or vehicle twice daily for 6 weeks.

Key facts

Study ID

NCT04091087

Run by

Pfizer

People needed

66

Starts

2020-06-26

Expected to finish

2021-10-19

Last updated by the study team

2022-05-02

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who are ≥45 years of age and in generally stable health
• Participants who are in generally stable health and have a known diagnosis of Stasis Dermatitis or newly diagnosed Stasis Dermatitis
• Participants whose mental and physical status allows them to be able to mostly perform their activities of daily living with minimal assistance

You may not qualify if…

• Participants with clinically significant active or potentially recurrent dermatitis conditions and known genetic dermatological conditions that are not Stasis Dermatitis or overlap with Stasis Dermatitis
• Participants with active venous stasis ulceration on either lower extremity.
• Participants with current infection or suspected infection of any Stasis Dermatitis lesions
• Women of child bearing potential (WOCBP) are not eligible for this study

Where it is running

• Lightship — El Segundo, California, United States
• Hawthorne Effect, Inc — Lafayette, California, United States
• Verily Life Sciences LLC — South San Francisco, California, United States
• Onco360 Oncology Pharmacy — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.